Vaccines train the adaptive immune system to recognize specific pathogens by producing targeted antibodies and memory cells, so the body can respond quickly if exposed again. This is not primarily about mucosal immunity; MMR mainly induces systemic antibody and T-cell responses that persist for most people, though antibody levels can eventually decline and protection can wane over time in some cases. After vaccination, circulating antibodies and memory cells provide protection. Boosters are used when immunity may weaken enough that exposure could lead to disease, or to ensure protection across a population, such as completing the two-dose MMR schedule. For MMR, the typical schedule includes two doses: the first at about 12–15 months and a second around 4–6 years old. This second dose helps ensure long-lasting immunity across the population, particularly since some individuals may not respond fully to the first dose. For tetanus, booster doses are given every 10 years (Td or Tdap), with a booster recommended sooner if a significant wound occurs and vaccination status isn’t up to date. This keeps protective antibody levels high, since tetanus immunity can wane over time. So, the idea that it mainly stimulates mucosal immunity, yields lifelong immunity with no boosters, and spares boosters altogether doesn’t align with how these vaccines work and how their schedules are designed.

The main idea is how ABO blood types are defined by surface antigens on red blood cells and the antibodies in plasma. In type B blood, red cells carry the B antigen, and the plasma has antibodies against the A antigen. If these cells encounter type A blood, the anti-A antibodies in the plasma recognize the A antigen on the donor red cells and bind to them, causing agglutination and potential hemolysis. This is why the combination described is B antigen on red cells with anti-A antibodies in the plasma.

The presence of A and B antigens on red blood cells, along with the Rh(D) antigen, defines AB positive. This is the only blood type that carries both A and B antigens and is Rh positive, so it uniquely has all three markers. If any one of those antigens is missing—A or B or Rh—the type would be different (for example, lacking Rh means negative, or lacking one of A/B means the absence of that antigen).

Lupus is a systemic autoimmune disease that can involve multiple organ systems. It commonly affects the kidneys (lupus nephritis), lungs (pleuritis or pneumonitis), joints (arthritis and arthralgias), and skin (malar or discoid rashes). It’s called a great imitator because its signs and symptoms are highly variable and can resemble many other conditions. Patients may present with joint pain, skin rashes, kidney problems, or neuropsychiatric symptoms that mimic other diseases, and the disease can wax and wane with periods of flare-up and remission. This broad, shifting presentation is what gives lupus its reputation as a great imitator. Other options are too limited (skin only) or focus on organs not typically primary targets, and they don’t capture the systemic, relapsing nature of the disease.